Taiho Oncology, Inc.

Taiho Oncology, Inc. is dedicated to enhancing the lives of cancer patients, their families, and caregivers through the development and commercialization of innovative treatments. Specializing in orally administered anti-cancer agents, Taiho Oncology is committed to providing effective solutions for a variety of tumor types.

Located at 101 Carnegie Center, Suite 101, Princeton, New Jersey 08540, US, Taiho Oncology operates with a robust pipeline of small molecule clinical candidates. These candidates target both solid tumor and hematological malignancies, with further advancements continually being made in pre-clinical development. As a subsidiary of Taiho Pharmaceutical Co., Ltd., which is part of Otsuka Holdings Co., Ltd., Taiho Oncology also oversees its parent company’s European and Canadian operations.

Taiho Oncology is focused on making significant strides in oncology. The company continually seeks to expand its reach and impact within the pharmaceutical industry. We invite the manager of Taiho Oncology, Inc. to create a customized and exclusive company showcase and product listing on our platform to further highlight their contributions and offerings.